Ionis Pharmaceuticals, Inc. (FRA:ISI)
Germany · Delayed Price · Currency is EUR | Market Cap | 11.37B +121.5% |
| Revenue (ttm) | 917.77M +47.5% |
| Net Income | -283.59M |
| EPS | -1.76 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 155 |
| Open | 67.96 |
| Previous Close | 67.38 |
| Day's Range | 67.96 - 71.86 |
| 52-Week Range | 33.50 - 72.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also ... [Read more]
Financial Performance
In 2025, Ionis Pharmaceuticals's revenue was $943.71 million, an increase of 33.83% compared to the previous year's $705.14 million. Losses were -$381.39 million, -15.97% less than in 2024.
Financial numbers in USD Financial StatementsNews
Ionis Pharmaceuticals price target raised to $130 from $125 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $130 from $125 and keeps a Buy rating on the shares following the FDA approval of Tryngolza. Published…
Ionis Pharmaceuticals enters zilganersen license agreement with Recordati
Ionis Pharmaceuticals (IONS) announced that it has entered into a license agreement with Recordati, under which Recordati obtained exclusive rights to develop and commercialize zilganersen, an investi...
Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement with Recordati (“Recordati”), under which Recordati obtained ...
Ionis Pharmaceuticals price target raised to $75 from $74 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $75 from $74 and keeps a Neutral rating on the shares. The firm cites the FDA having approved…
Ionis Pharmaceuticals Transcript: FDA announcement
TRYNGOLZA received FDA approval as the first therapy to reduce triglycerides and acute pancreatitis risk in adults with sHTG, supported by robust phase III data showing up to 72% triglyceride reduction and 91% reduction in pancreatitis events. The launch will focus on high-risk patients, with broad payer access and strong support programs expected to drive adoption.
Ionis Pharmaceuticals Slides: FDA announcement
Ionis Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 24, 2026.
Ionis Pharmaceuticals Press release: FDA announcement
Ionis Pharmaceuticals issued a press release on June 24, 2026, disclosing material business information to investors.
FDA approves Ionis’ Tryngolza as adjunct to diet to reduce triglycerides
Ionis Pharmaceuticals (IONS) announced that the U.S. Food and Drug Administration has approved TRYNGOLZA s an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults…
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA® (olezarsen) as an adjunct to diet...
FDA announces approval of Ionis’ Tryngolza for hypertriglyceridemia
The Food and Drug Administration said it has approved Ionis Pharmaceuticals (IONS)’ Tryngolza, used with diet, to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertri...
Ionis Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Transitioning to a commercial-stage biotech, the company is launching new products in cardiometabolic and neurology, with TRYNGOLZA and DAWNZERA leading growth. Key catalysts include FDA decisions, robust revenue guidance, and a $3B+ peak sales outlook for TRYNGOLZA, supported by strategic pricing and strong pipeline momentum.
Ionis Pharmaceuticals Slides: FY 2026
Ionis Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 10, 2026.
Ionis Pharmaceuticals appoints Hantson to Board of Directors
Ionis Pharmaceuticals (IONS) announced the appointment of Ludwig Hantson, Ph.D. to the Ionis Board of Directors, effective immediately. Before joining Alexion, Dr. Hantson served as president of Baxte...
Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Ludwig Hantson, Ph.D., an accomplished global biopharmaceutical leader, to the Ionis Bo...
Ionis Pharmaceuticals Transcript: AGM 2026
Accelerated transformation to a commercial-stage biotech has driven strong revenue growth and multiple independent product launches. A robust late-stage pipeline in cardiometabolic and neurology, combined with innovative RNA-targeted technologies, positions the company for over $7 billion in peak annual revenue and break-even cash flow by 2028.
Ionis Pharmaceuticals Slides: FY 2026
Ionis Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 4, 2026.
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data analyses from the landmark Phase 3 CORE and CORE2 studies of olezarsen in people with severe...
Ionis partner GSK reports B-Well 1, B-Well 2 trials meet primary endpoint
Ionis Pharmaceuticals (IONS) partner GSK (GSK) announced data for bepirovirsen, an investigational antisense oligonucleotide for the treatment of chronic hepatitis B. Results from the two Phase 3 tria...
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligonucleotide (ASO) for...
Ionis Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026
Significant pipeline progress includes two recent launches, multiple phase III readouts in 2026, and robust data for SHTG, tau, and rare neurology programs. Pricing and revenue guidance reflect strong demand, while market expansion is anticipated with new entrants. Key upcoming milestones include PDUFA dates and pivotal trial results.
Ionis Pharmaceuticals initiated with a Buy, named a top pick at Citi
Citi initiated coverage of Ionis Pharmaceuticals (IONS) with a Buy rating and $115 price target and named it a top pick among small-to-mid cap biotech stocks. Tryngloza for severe hypertriglyceridemia...
Ionis Pharmaceuticals participates in a conference call with Cantor
Conference call with management will be held on May 15 at 11 am hosted by Cantor.Webcast Link
Ionis announces Biogen’s CELIA study did not meet primary endpoint
Ionis Pharmaceuticals (IONS) announced that its partner, Biogen (BIIB), shared compelling topline results from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleoti...
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared compelling topline results from the Phase 2 CELIA study evaluating dirane...
Ionis Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
The company reported robust commercial growth with INGREZZA, CRENESSITY, and VYKAT XR, and is advancing a broad pipeline with key phase III readouts expected in 2027–2028. Rare disease launches are driving rapid adoption, and the Soleno acquisition strengthens the rare endocrine portfolio.